We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
 Elexopharm Enters Into Cardiovascular Collaboration With Merck & Co.
News

Elexopharm Enters Into Cardiovascular Collaboration With Merck & Co.

 Elexopharm Enters Into Cardiovascular Collaboration With Merck & Co.
News

Elexopharm Enters Into Cardiovascular Collaboration With Merck & Co.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of " Elexopharm Enters Into Cardiovascular Collaboration With Merck & Co."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ElexoPharm GmbH has announced a collaboration and exclusive worldwide license agreement with Merck & Co., Inc. Whitehouse Station, New Jersey USA (also known as MSD outside of the US and Canada) through an affiliate to develop and commercialize novel candidates targeting aldosterone synthase for the potential treatment of cardiovascular disease.

Under the terms of the agreement, Merck will pay ElexoPharm an upfront payment of €1.5 million. In addition ElexoPharm is eligible to receive up to an additional €32.3 million if specific development, regulatory and commercial milestones are achieved for a candidate and royalties on net sales of any products resulting from the collaboration. Merck is responsible for development, regulatory filings, manufacturing and commercialization activities.

“This agreement marks a major milestone in ElexoPharm’s relatively recent company history," said Axel Koch, Managing Director of ElexoPharm GmbH, "We are delighted to have a partner such as Merck.”

"This agreement with ElexoPharm underscores Merck's ongoing commitment to developing breakthrough cardiovascular medicines," said Andrew Plump, M.D., vice president, cardiovascular disease discovery research, Merck Research Laboratories.
Advertisement